Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

Amid rising concerns over a possible fresh wave of COVID-19 cases across the country, the Tamil Nadu government has announced ...

A talk with the author of new research suggesting that an ADC may offer practice-changing, patient-friendly treatment of ...

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod; RHO data show efgartigimod achieved susta ...

PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with ...

dDepartment of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring, Australia ePlasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland ...

The FDA has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 antibody, for the treatment of celiac disease.

Learn how antibody to payload design is crucial for advancing ADC technology in oncology and beyond with expert insights.